Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
April 25 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, will release financial results for
the quarter ended March 31, 2022, after the market close on
Wednesday, May 11, 2022. Ron Rocca, Exagen’s President and Chief
Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark
Hazeltine, Chief Operating Officer, will host a conference call to
review the Company’s results at 4:30 PM ET (1:30 PM PT).
Interested parties may access the conference call by dialing
(855) 238-9398 (U.S.) or (412) 317-5230 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
investors.exagen.com.
A replay of the conference call will be available until
Wednesday, May 18, 2022, at 11:59 PM ET (8:59 PM PT). Interested
parties may access the replay of the conference call by dialing
(844) 512-2921 (U.S.) or (412) 317-6671 (international) using
passcode 10166625. Additionally, a recording of the webcast will be
available using the link on the Exagen investor relations website
approximately 30 minutes after the call concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus.
For more information, please visit Exagen.com and follow
@ExagenInc on Twitter.
CONTACTS:
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024